TY - JOUR
T1 - DNA damage stress-induced translocation of mutant FUS proteins into cytosolic granules and screening for translocation inhibitors
AU - Nogami, Masahiro
AU - Sano, Osamu
AU - Adachi-Tominari, Keiko
AU - Hayakawa-Yano, Yoshika
AU - Furukawa, Takako
AU - Iwata, Hidehisa
AU - Ogi, Kazuhiro
AU - Okano, Hideyuki
AU - Yano, Masato
N1 - Funding Information:
We thank Hiroyuki Kato, Takahisa Ogasawara, Sho Ninomiya, Yukinobu Hayashi and Airi Hasegawa for technical assistance. We also thank Hajime Komano, Masato Yugami, and Tsuyoshi Matsuo for valuable discussions. We would like to express our deep appreciation to Masaaki Funata, Principal Scientist of Neuroscience DDU-iBL, for his help in searching for structurally related compounds from the 1st screening hit compounds in conducting this research. We would like to thank the Neuroscience Drug Discovery Unit (DDU)-Innovative Biology Laboratories (iBL) for their support. Finally, we would like to thank Yoshiyuki Tsujihata, Director, and Keiji Yamamoto, Senior director of Neuroscience DDU-iBL, for giving us the opportunity to conduct this research.
Funding Information:
This work was supported by grants from the SIL Research Fund from Takeda Pharmaceutical Company, Ltd., Japan and a Grant-in-Aid for Scientific Research from the JSPS (grant number JP20H00485a) to MY and HO. This work is also supported by a Grant-in-Aid for Transformative Research Areas (A) from The MEXT (grant number JP22H05589) and a Grant-in-Aid for Scientific Research from the JSPS (grant number P19H03543), the Takeda Science Foundation, Japan, Takeda-COCKPI-T and the SERIKA Fund to MY the Takeda Science Foundation and the ALS Foundation (Japan ALS Association) to YH-Y.
Publisher Copyright:
Copyright © 2022 Nogami, Sano, Adachi-Tominari, Hayakawa-Yano, Furukawa, Iwata, Ogi, Okano and Yano.
PY - 2022/12/20
Y1 - 2022/12/20
N2 - Fused in sarcoma/translated in liposarcoma (FUS) is an RNA-binding protein, and its mutations are associated with neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), through the DNA damage stress response, aberrant stress granule (SG) formation, etc. We previously reported that translocation of endogenous FUS into SGs was achieved by cotreatment with a DNA double-strand break inducer and an inhibitor of DNA-PK activity. In the present study, we investigated cytoplasmic SG formation using various fluorescent protein-tagged mutant FUS proteins in a human astrocytoma cell (U251) model. While the synergistic enhancement of the migration of fluorescent protein-tagged wild-type FUS to cytoplasmic SGs upon DNA damage induction was observed when DNA-PK activity was suppressed, the fluorescent protein-tagged FUSP525L mutant showed cytoplasmic localization. It migrated to cytoplasmic SGs upon DNA damage induction alone, and DNA-PK inhibition also showed a synergistic effect. Furthermore, analysis of 12 sites of DNA-PK–regulated phosphorylation in the N-terminal LC region of FUS revealed that hyperphosphorylation of FUS mitigated the mislocalization of FUS into cytoplasmic SGs. By using this cell model, we performed screening of a compound library to identify compounds that inhibit the migration of FUS to cytoplasmic SGs but do not affect the localization of the SG marker molecule G3BP1 to cytoplasmic SGs. Finally, we successfully identified 23 compounds that inhibit FUS-containing SG formation without changing normal SG formation. Highlights: Characterization of DNA-PK-dependent FUS stress granule localization. A compound library was screened to identify compounds that inhibit the formation of FUS-containing stress granules.
AB - Fused in sarcoma/translated in liposarcoma (FUS) is an RNA-binding protein, and its mutations are associated with neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), through the DNA damage stress response, aberrant stress granule (SG) formation, etc. We previously reported that translocation of endogenous FUS into SGs was achieved by cotreatment with a DNA double-strand break inducer and an inhibitor of DNA-PK activity. In the present study, we investigated cytoplasmic SG formation using various fluorescent protein-tagged mutant FUS proteins in a human astrocytoma cell (U251) model. While the synergistic enhancement of the migration of fluorescent protein-tagged wild-type FUS to cytoplasmic SGs upon DNA damage induction was observed when DNA-PK activity was suppressed, the fluorescent protein-tagged FUSP525L mutant showed cytoplasmic localization. It migrated to cytoplasmic SGs upon DNA damage induction alone, and DNA-PK inhibition also showed a synergistic effect. Furthermore, analysis of 12 sites of DNA-PK–regulated phosphorylation in the N-terminal LC region of FUS revealed that hyperphosphorylation of FUS mitigated the mislocalization of FUS into cytoplasmic SGs. By using this cell model, we performed screening of a compound library to identify compounds that inhibit the migration of FUS to cytoplasmic SGs but do not affect the localization of the SG marker molecule G3BP1 to cytoplasmic SGs. Finally, we successfully identified 23 compounds that inhibit FUS-containing SG formation without changing normal SG formation. Highlights: Characterization of DNA-PK-dependent FUS stress granule localization. A compound library was screened to identify compounds that inhibit the formation of FUS-containing stress granules.
KW - FUS
KW - RNA-binding protein
KW - amyotrophic lateral scelerosis
KW - compound library screening
KW - stress granule
UR - http://www.scopus.com/inward/record.url?scp=85145452755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145452755&partnerID=8YFLogxK
U2 - 10.3389/fnmol.2022.953365
DO - 10.3389/fnmol.2022.953365
M3 - Article
AN - SCOPUS:85145452755
SN - 1662-5099
VL - 15
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
M1 - 953365
ER -